GCP
MREO

GSA Capital Partners’s Mereo BioPharma MREO Stock Holding History

GSA Capital Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-58,145
Closed -$120K – 1943
2025
Q3 		$120K Buy
+58,145
New +$107K 0.01% 1508
2024
Q4 		– Sell
-67,069
Closed -$276K – 1867
2024
Q3 		$276K Buy
+67,069
New +$277K 0.02% 1260
2024
Q2 		– Sell
-75,787
Closed -$250K – 1892
2024
Q1 		$250K Buy
+75,787
New +$257K 0.02% 1304
2023
Q1 		– Sell
-72,740
Closed -$55K – 1770
2022
Q4 		$55K Buy
+72,740
New +$59.7K 0.01% 1354

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

GSA Capital Partners's MREO Position: Q4 2025 in Review

GSA Capital Partners sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 58,145 shares — an estimated $120K sold.

GSA Capital Partners first reported a position in MREO in Q4 2022 and held it in 4 quarters. The position peaked at $276K in Q3 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • GSA Capital Partners reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 58,145 Mereo BioPharma shares in Q4 2025, an estimated $120K.
  • GSA Capital Partners first reported a position in Mereo BioPharma in Q4 2022 and held it in 4 quarters.
  • GSA Capital Partners's Mereo BioPharma position peaked at $276K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.